Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

RVNC Price Correlated With Financials For Revance Therapeutics

Free historical financial statements for Revance Therapeutics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 33 quarters since 2014. Compare with RVNC stock chart to see long term trends.

RVNC Stock Compared to Quarterly

RVNC Income Statement

Revenue, Net:25261000
Revenue Per Share:0.3471
Selling, General & Admin Expense:45075000
Research & Development Expense:30729000
Total Operating Expenses:87482000
Operating Income:-62221000
Income Taxes:null
Net Income:-64342000
Earnings Per Share, Basic:-0.94
Shares Outstanding, Basic Avg:72768161

RVNC Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:5376000
Change in Accounts Receiveable:1123000
Net Cash from Operations:-61270000
Net Cash from Operations Per Share:-0.842
Net Cash from Financing Activities:105313000
Property, Plant & Equipment Purchases:1456000
Net Cash from Investing Activities:44568000
Net Change in Cash & Equivalents:88611000

RVNC Balance Sheet

Cash and Cash Equivalents:262600000
Short-Term Investments:64231000
Accounts Receivable, Net:4471000
Total Current Assets:285330000
Property, Plant & Equipment, Net:23496000
Total Assets:639546000
Accounts Payable:10020000
Total Short-Term Liabilities:71066000
Total Liabilities:614005000
The Company Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting, neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed Phase 3 programs for DaxibotulinumtoxinA for Injection across two different treatment categories, aesthetics and therapeutics. In the aesthetics category, we completed our Phase 3 program for the treatment of moderate to severe glabellar (frown) lines and are pursuing United States (“U.S.”) regulatory approval. In the therapeutics category, we completed our Phase 3 program for the treatment of cervical dystonia in November 2021 and plan to pursue U.S. regulatory approval following the FDA approval of DaxibotulinumtoxinA for Injection for glabellar lines. We are also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. To complement DaxibotulinumtoxinA for Injection, we own a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA approved fillers for correction of dynamic facial wrinkles and folds, and OPUL™. We have also partnered with Viatris to develop an onabotulinumtoxinA biosimilar, which would compete in the existing short-acting neuromodulator marketplace.

Since inception, we have devoted substantial efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the onabotulinumtoxinA biosimilar, and the commercial launch of our products and services. As a result, we have incurred losses and negative cash flows from operations.

Liquidity and Going Concern

For the year ended December 31, 2021, we had a net loss of $281.3 million. As of December 31, 2021, we had a working capital surplus of $178.8 million and an accumulated deficit of $1.4 billion. In recent years, we have funded our operations primarily through the sale of common stock, convertible senior notes, payments received from collaboration arrangements, and sales of the RHA® Collection of dermal fillers. As of December 31, 2021, we had capital resources of $225.1 million consisting of cash, cash equivalents, and short-term investments.

On October 15, 2021, the FDA issued a Complete Response Letter (“CRL”) regarding our BLA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines. The FDA indicated it was unable to approve the BLA in its present form due to deficiencies related to the FDA’s onsite inspection at our manufacturing facility. As a result, the potential commercial launch of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines has been delayed. The commercial launch delay and its impact on our capital resources has raised substantial doubt with respect to our ability to meet our obligations to continue as a going concern. Our existing cash, cash equivalents, and short-term investments will not allow us to fund our operations for at least 12 months following the filing of this Report.

In order to mitigate the substantial doubt to continue as a going concern, we will be required to raise additional capital to fund our operations. We will seek additional capital through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations. Additional capital may

Data imported from Revance Therapeutics Inc SEC filings. Check original filings before making any investment decision.